Is taltz safe?

Is Taltz safe for most people who receive it?

Taltz carries an FDA boxed warning for increased risk of serious infections, including tuberculosis reactivation and invasive fungal disease. Patients must be screened for latent TB before starting treatment, and any active infection requires resolution first.

What infections are most common with Taltz?

Upper-respiratory-tract infections occur in roughly 14 percent of users. Other frequent events include injection-site reactions, nausea, and oral candidiasis. Rare but serious adverse effects include inflammatory bowel disease flares and hypersensitivity reactions.

How does Taltz affect people with pre-existing conditions?

Individuals with active infections, inflammatory bowel disease, or a history of recurrent infections face higher complication rates. Liver-enzyme elevations have been reported, so baseline and periodic monitoring is recommended. Taltz is not recommended during active tuberculosis or serious opportunistic infections.

Can Taltz be used during pregnancy or breastfeeding?

Limited human data exist; animal studies showed no direct embryo-fetal toxicity at clinically relevant doses, yet the drug crosses the placenta. Current guidance advises weighing potential benefits against unknown fetal risk and considering alternatives when possible. Breastfeeding mothers should discuss timing with their clinician because IgG antibodies can pass into milk.

Does Taltz interact with other medicines?

Live vaccines are contraindicated during therapy. Combination with other immunosuppressants raises infection risk further. No clinically significant pharmacokinetic interactions with CYP substrates have been identified.

When does the Taltz patent expire?

The composition-of-matter patent listed in FDA records expires in 2026, with possible pediatric exclusivity extending protection into 2027. Biosimilar entry is therefore unlikely before late 2026 at the earliest.

Who makes Taltz and what are current pricing details?

Eli Lilly manufactures Taltz. Wholesale acquisition cost for one 80 mg autoinjector exceeds $5,500 in the United States, and annual therapy cost often surpasses $60,000 without insurance or assistance programs. Copay cards and patient-support programs can reduce out-of-pocket expense for eligible patients.

How does Taltz compare with other IL-17 inhibitors?

Taltz shows similar efficacy to secukinumab (Cosentyx) in psoriasis and psoriatic arthritis trials, with possibly faster skin-clearance rates in some head-to-head data. Safety profiles are comparable, though each agent carries its own post-marketing signals for inflammatory bowel disease.

Are biosimilars expected soon?

No approved biosimilars for ixekizumab are on the market. Several candidates are in development, but regulatory and litigation timelines suggest first launches remain at least two years away.

What real-world safety data exist beyond clinical trials?

Post-marketing surveillance through FAERS and published cohort studies has confirmed the infection signals seen in trials, with no new major safety concerns emerging to date. Long-term extension studies up to five years show sustained tolerability when patients are appropriately screened and monitored.